NASDAQ · WHWK
Whitehawk Therapeutics Inc
Healthcare · Biotechnology
$3.760.00% ($0.00)at close
After hours$3.74▼ 0.53%7:30 PM ET
Market cap
$214.35M
P/E
-3.36
EPS (TTM)
-$0.96
Next earnings
Nov 5, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Data notes
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
- 10-yr revenue CAGR
- 0.8%
- Ending operating margin
- 0.0%
- Discount rate
- 9.7%
USD · FY 2025 · Price used $3.76 · Price Oct 1, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 96.86% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow grew 28.13% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive move in revenue — currently down 100% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
Market multiples
Stock splits
Every 1 shares became 15
Every 1 shares became 2
Profitability & growth
Analyst consensus
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 5, 2026
Q3 FY26 · EPS est -$0.27 · Revenue est —
View
Institutional Sentiment
Whitehawk Therapeutics Inc · WHWK
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.